Autopsy report · NCT01790594

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

“Slow accrual within enrollment time period: projected accrual goal not achieved.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 6 months before it stopped.
• 46 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor type

US National Institutes of Health

Conditions

Simultaneous Kidney and Pancreas Transplantation

Interventions

Belatacept; methylprednisolone; Anti-thymocyte Globulin (Rabbit); Tacrolimus; Mycophenolate mofetil

Participants

46

Sites

5

Countries

United States

Trials that died the same way

• tDCS and Cognitive Training for Restrictive Eating Disorders
  “Slow accrual/low enrollment” (83% match in meaning)
• Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
  “Slow enrollment and financial constraints.” (75% match in meaning)
• A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy
  “Slow enrollment” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.